Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Here are three reasons why there are better opportunities than TXG and a stock we'd rather own. Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

B iotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 ...

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...